Public Policy Resources

ACS CAN Supports the DIVERSE Trials Act (H.R. 5030/S. 2706)

September 2, 2021

Clinical trials are key to advancing new standards of care that can improve survival and quality of life for people with cancer. However, cost to trial participants is often a barrier to their enrollment. Patients are frequently responsible for non-medical costs such as transportation and lodging associated with trial enrollment. Offering to reimburse patients for ancillary costs associated with trials can increase overall enrollment and may also increase participation from underrepresented groups. The bipartisan DIVERSE Trials Act (H.R. 5030/S. 2706) could increase diversity in clinical trials and make it easier for all people with cancer to participate in clinical trials by reducing financial and geographic barriers to enrollment.

PDF icon Download DIVERSE Trials Act Factsheet

Related Resources

July 10, 2023

Cómo reducir las inequidades del cáncer para la comunidad LGBTQ+

Las comunidades de personas lesbianas, homosexuales, bisexuales, transgénero y queer/indefinido (LGBTQ+) enfrentan serios desafíos, sesgos y obstáculos para la detección del cáncer y la atención médica. La Sociedad Americana Contra el Cáncer estima que podría haber casi 152,000 casos de cáncer nuevos y 50,000 muertes por cáncer entre las personas LGBTQ+ en 2023.

Read More

Survivor Views: Discrimination Among LGBTQ+ Cancer Patients

June 26, 2023

Half of Lesbian, Gay, Bisexual, Transgender, and Queer/Questioning (LGBTQ+) cancer patients and survivors report they are concerned about facing discrimination in a health care setting. More than one-third have experienced discrimination in a healthcare setting, with significant impacts on their care.

Read more

Medicaid Work or Community Engagement Requirements Could Harm People with Cancer and Cancer Survivors

April 25, 2023

ACS CAN strongly opposes any attempt by the federal government or states to condition Medicaid coverage on work or community engagement.

Read more